Processa Pharmaceuticals Inc (NASDAQ: PCSA) kicked off on Monday, down -8.83% from the previous trading day, before settling in for the closing price of $0.3. Over the past 52 weeks, PCSA has traded in a range of $0.15-$1.50.
A company in the Healthcare sector has jumped its sales by 22.65% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 88.37%. With a float of $49.24 million, this company’s outstanding shares have now reached $52.86 million.
Processa Pharmaceuticals Inc (PCSA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Processa Pharmaceuticals Inc is 13.07%, while institutional ownership is 3.14%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.74 earnings per share (EPS), higher than consensus estimate (set at -0.92) by 0.18.
According to the Wall Street analysts, stocks earnings will be around 88.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 59.35% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Take a look at Processa Pharmaceuticals Inc’s (PCSA) current performance indicators. Last quarter, stock had a quick ratio of 3.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.23 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.45 million. That was inferior than the volume of 9.16 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.77%.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 28.16%, which indicates a significant increase from 3.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0465 in the past 14 days, which was higher than the 0.0306 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2880, while its 200-day Moving Average is $0.3090. However, in the short run, Processa Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2976. Second resistance stands at $0.3218. The third major resistance level sits at $0.3363. If the price goes on to break the first support level at $0.2589, it is likely to go to the next support level at $0.2444. Assuming the price breaks the second support level, the third support level stands at $0.2202.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
The company with the Market Capitalisation of 15.49 million has total of 56,644K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -11,850 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -3,440 K.
